Auricula Biosciences Inc.

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
KRAS (mutant; tumor-selective delivery via macropinocytosis) with a tubulin-targeting cytotoxic payloadOther
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
WEF-001Phase 1/2Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer …
Est. primary completion 2028-01 · NCT07148128 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.